Skip to content
Study details
Enrolling now

Bacteriophage Therapy Trial

Barbara Trautner
NCT IDNCT06559618ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

30

Study length

about 1.9 years

Ages

18+

Locations

2 sites in MO, TX

What this study is about

This trial is testing the safety of a phage treatment in adults with spinal cord injuries and bacteriuria. Participants will receive either phage therapy or a placebo for 696 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Take Phage Therapy

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: To evaluate the safety and tolerability of phage therapy in adults ≥18 years of age with spinal cord injury (SCI) and bacteriuria with Escherichia coli (E. coli)

Secondary: To evaluate of the pharmacodynamics (PD) of investigational phage therapy, To evaluate the pharmacokinetics (PK) of investigational phage therapy

Body systems

Neurology